Is BLCO or NEOG more profitable?

Neogen has a net margin of -0.91% compared to Bausch + Lomb's net margin of -3.21%. Bausch + Lomb's return on equity of 4.14% beat Neogen's return on equity. Company Net Margins Return on Equity Return on Assets Bausch + Lomb -3.21% 4.14% 1.93% Neogen -0.91% 2.78% 1.74%

Does the media prefer BLCO or NEOG?

In the previous week, Neogen had 7 more articles in the media than Bausch + Lomb. MarketBeat recorded 11 mentions for Neogen and 4 mentions for Bausch + Lomb. Bausch + Lomb's average media sentiment score of 0.52 beat Neogen's score of 0.45 indicating that Bausch + Lomb is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bausch + Lomb 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neogen 2 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, NVST or NEOG?

Envista has higher revenue and earnings than Neogen. Neogen is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Envista $2.72B 1.38 $47M $0.58 40.31 Neogen $870.40M 3.26 -$7.90M -$0.03 N/A

Is NVST or NEOG more profitable?

Envista has a net margin of 3.33% compared to Neogen's net margin of -0.91%. Envista's return on equity of 7.88% beat Neogen's return on equity. Company Net Margins Return on Equity Return on Assets Envista 3.33% 7.88% 4.33% Neogen -0.91% 2.78% 1.74%

Does the media refer more to NVST or NEOG?

In the previous week, Envista had 7 more articles in the media than Neogen. MarketBeat recorded 18 mentions for Envista and 11 mentions for Neogen. Envista's average media sentiment score of 0.52 beat Neogen's score of 0.45 indicating that Envista is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Envista 4 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neogen 2 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, NEOG or ICUI?

ICU Medical has higher revenue and earnings than Neogen. Neogen is trading at a lower price-to-earnings ratio than ICU Medical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neogen $870.40M 3.26 -$7.90M -$0.03 N/A ICU Medical $2.16B 1.77 $730K $1.18 129.36

Is NEOG or ICUI more profitable?

ICU Medical has a net margin of 1.39% compared to Neogen's net margin of -0.91%. ICU Medical's return on equity of 7.91% beat Neogen's return on equity. Company Net Margins Return on Equity Return on Assets Neogen -0.91% 2.78% 1.74% ICU Medical 1.39% 7.91% 4.17%

Does the media prefer NEOG or ICUI?

In the previous week, Neogen had 3 more articles in the media than ICU Medical. MarketBeat recorded 11 mentions for Neogen and 8 mentions for ICU Medical. ICU Medical's average media sentiment score of 0.65 beat Neogen's score of 0.45 indicating that ICU Medical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neogen 2 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral ICU Medical 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor NEOG or XRAY?

In the previous week, Neogen had 5 more articles in the media than DENTSPLY SIRONA. MarketBeat recorded 11 mentions for Neogen and 6 mentions for DENTSPLY SIRONA. Neogen's average media sentiment score of 0.45 beat DENTSPLY SIRONA's score of 0.16 indicating that Neogen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neogen 2 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral DENTSPLY SIRONA 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Neogen (NEOG) Competitors

$13.00 +0.17 (+1.33%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$13.30 +0.30 (+2.27%)

As of 09/18/2026 07:30 PM Eastern

Compare

NEOG vs. BLCO, MMSI, NVST, ICUI, and XRAY

Should you buy Neogen stock or one of its competitors? Neogen's main competitors and comparable companies include Bausch + Lomb (BLCO), Merit Medical Systems (MMSI), Envista (NVST), ICU Medical (ICUI), and DENTSPLY SIRONA (XRAY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare supplies" industry.

How does Neogen compare to Bausch + Lomb?

Bausch + Lomb (NYSE:BLCO) and Neogen (NASDAQ:NEOG) are both mid-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Neogen has lower revenue, but higher earnings than Bausch + Lomb. Neogen is trading at a lower price-to-earnings ratio than Bausch + Lomb, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch + Lomb	$5.10B	1.18	-$360M	-$0.48	N/A
Neogen	$870.40M	3.26	-$7.90M	-$0.03	N/A

In the previous week, Neogen had 7 more articles in the media than Bausch + Lomb. MarketBeat recorded 11 mentions for Neogen and 4 mentions for Bausch + Lomb. Bausch + Lomb's average media sentiment score of 0.52 beat Neogen's score of 0.45 indicating that Bausch + Lomb is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bausch + Lomb	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neogen	2 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Neogen has a net margin of -0.91% compared to Bausch + Lomb's net margin of -3.21%. Bausch + Lomb's return on equity of 4.14% beat Neogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch + Lomb	-3.21%	4.14%	1.93%
Neogen	-0.91%	2.78%	1.74%

Bausch + Lomb has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market. Comparatively, Neogen has a beta of 1.76, indicating that its stock price is 76% more volatile than the broader market.

Bausch + Lomb presently has a consensus target price of $19.15, suggesting a potential upside of 13.78%. Neogen has a consensus target price of $12.00, suggesting a potential downside of 7.69%. Given Bausch + Lomb's higher possible upside, equities research analysts plainly believe Bausch + Lomb is more favorable than Neogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch + Lomb	1 Sell rating(s)	8 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.33
Neogen	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

11.1% of Bausch + Lomb shares are owned by institutional investors. Comparatively, 96.7% of Neogen shares are owned by institutional investors. 1.5% of Bausch + Lomb shares are owned by company insiders. Comparatively, 0.5% of Neogen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Bausch + Lomb and Neogen tied by winning 8 of the 16 factors compared between the two stocks.

How does Neogen compare to Merit Medical Systems?

Neogen (NASDAQ:NEOG) and Merit Medical Systems (NASDAQ:MMSI) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, media sentiment, valuation, dividends, risk and profitability.

Merit Medical Systems has higher revenue and earnings than Neogen. Neogen is trading at a lower price-to-earnings ratio than Merit Medical Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neogen	$870.40M	3.26	-$7.90M	-$0.03	N/A
Merit Medical Systems	$1.52B	3.36	$128.49M	$2.42	35.28

Merit Medical Systems has a net margin of 9.22% compared to Neogen's net margin of -0.91%. Merit Medical Systems' return on equity of 13.75% beat Neogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neogen	-0.91%	2.78%	1.74%
Merit Medical Systems	9.22%	13.75%	8.10%

96.7% of Neogen shares are owned by institutional investors. Comparatively, 99.7% of Merit Medical Systems shares are owned by institutional investors. 0.5% of Neogen shares are owned by insiders. Comparatively, 0.7% of Merit Medical Systems shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Neogen had 11 more articles in the media than Merit Medical Systems. MarketBeat recorded 11 mentions for Neogen and 0 mentions for Merit Medical Systems. Merit Medical Systems' average media sentiment score of 1.85 beat Neogen's score of 0.45 indicating that Merit Medical Systems is being referred to more favorably in the news media.

Company	Overall Sentiment
Neogen	Neutral
Merit Medical Systems	Very Positive

Neogen has a beta of 1.76, indicating that its stock price is 76% more volatile than the broader market. Comparatively, Merit Medical Systems has a beta of 0.49, indicating that its stock price is 51% less volatile than the broader market.

Neogen currently has a consensus target price of $12.00, suggesting a potential downside of 7.69%. Merit Medical Systems has a consensus target price of $100.00, suggesting a potential upside of 17.14%. Given Merit Medical Systems' stronger consensus rating and higher possible upside, analysts plainly believe Merit Medical Systems is more favorable than Neogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neogen	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Merit Medical Systems	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.83

Summary

Merit Medical Systems beats Neogen on 15 of the 17 factors compared between the two stocks.

How does Neogen compare to Envista?

Envista (NYSE:NVST) and Neogen (NASDAQ:NEOG) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations, media sentiment and institutional ownership.

Envista has higher revenue and earnings than Neogen. Neogen is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Envista	$2.72B	1.38	$47M	$0.58	40.31
Neogen	$870.40M	3.26	-$7.90M	-$0.03	N/A

Envista has a net margin of 3.33% compared to Neogen's net margin of -0.91%. Envista's return on equity of 7.88% beat Neogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Envista	3.33%	7.88%	4.33%
Neogen	-0.91%	2.78%	1.74%

Envista has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market. Comparatively, Neogen has a beta of 1.76, indicating that its stock price is 76% more volatile than the broader market.

Envista presently has a consensus target price of $29.86, indicating a potential upside of 27.70%. Neogen has a consensus target price of $12.00, indicating a potential downside of 7.69%. Given Envista's stronger consensus rating and higher possible upside, equities analysts clearly believe Envista is more favorable than Neogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Envista	0 Sell rating(s)	9 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.53
Neogen	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

96.7% of Neogen shares are held by institutional investors. 1.0% of Envista shares are held by insiders. Comparatively, 0.5% of Neogen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Envista had 7 more articles in the media than Neogen. MarketBeat recorded 18 mentions for Envista and 11 mentions for Neogen. Envista's average media sentiment score of 0.52 beat Neogen's score of 0.45 indicating that Envista is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Envista	4 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neogen	2 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Envista beats Neogen on 14 of the 17 factors compared between the two stocks.

How does Neogen compare to ICU Medical?

Neogen (NASDAQ:NEOG) and ICU Medical (NASDAQ:ICUI) are both mid-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings.

ICU Medical has a net margin of 1.39% compared to Neogen's net margin of -0.91%. ICU Medical's return on equity of 7.91% beat Neogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neogen	-0.91%	2.78%	1.74%
ICU Medical	1.39%	7.91%	4.17%

ICU Medical has higher revenue and earnings than Neogen. Neogen is trading at a lower price-to-earnings ratio than ICU Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neogen	$870.40M	3.26	-$7.90M	-$0.03	N/A
ICU Medical	$2.16B	1.77	$730K	$1.18	129.36

Neogen currently has a consensus target price of $12.00, indicating a potential downside of 7.69%. ICU Medical has a consensus target price of $192.80, indicating a potential upside of 26.30%. Given ICU Medical's stronger consensus rating and higher possible upside, analysts clearly believe ICU Medical is more favorable than Neogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neogen	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
ICU Medical	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.89

96.7% of Neogen shares are held by institutional investors. Comparatively, 96.1% of ICU Medical shares are held by institutional investors. 0.5% of Neogen shares are held by insiders. Comparatively, 2.1% of ICU Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Neogen had 3 more articles in the media than ICU Medical. MarketBeat recorded 11 mentions for Neogen and 8 mentions for ICU Medical. ICU Medical's average media sentiment score of 0.65 beat Neogen's score of 0.45 indicating that ICU Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neogen	2 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
ICU Medical	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Neogen has a beta of 1.76, suggesting that its stock price is 76% more volatile than the broader market. Comparatively, ICU Medical has a beta of 0.75, suggesting that its stock price is 25% less volatile than the broader market.

Summary

ICU Medical beats Neogen on 13 of the 17 factors compared between the two stocks.

How does Neogen compare to DENTSPLY SIRONA?

Neogen (NASDAQ:NEOG) and DENTSPLY SIRONA (NASDAQ:XRAY) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, valuation and earnings.

Neogen currently has a consensus target price of $12.00, suggesting a potential downside of 7.69%. DENTSPLY SIRONA has a consensus target price of $13.31, suggesting a potential upside of 39.49%. Given DENTSPLY SIRONA's higher possible upside, analysts clearly believe DENTSPLY SIRONA is more favorable than Neogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neogen	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
DENTSPLY SIRONA	3 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.00

96.7% of Neogen shares are owned by institutional investors. Comparatively, 95.7% of DENTSPLY SIRONA shares are owned by institutional investors. 0.5% of Neogen shares are owned by company insiders. Comparatively, 0.5% of DENTSPLY SIRONA shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Neogen had 5 more articles in the media than DENTSPLY SIRONA. MarketBeat recorded 11 mentions for Neogen and 6 mentions for DENTSPLY SIRONA. Neogen's average media sentiment score of 0.45 beat DENTSPLY SIRONA's score of 0.16 indicating that Neogen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neogen	2 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
DENTSPLY SIRONA	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Neogen has higher earnings, but lower revenue than DENTSPLY SIRONA. Neogen is trading at a lower price-to-earnings ratio than DENTSPLY SIRONA, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neogen	$870.40M	3.26	-$7.90M	-$0.03	N/A
DENTSPLY SIRONA	$3.68B	0.52	-$598M	-$2.75	N/A

Neogen has a beta of 1.76, suggesting that its share price is 76% more volatile than the broader market. Comparatively, DENTSPLY SIRONA has a beta of 0.84, suggesting that its share price is 16% less volatile than the broader market.

Neogen has a net margin of -0.91% compared to DENTSPLY SIRONA's net margin of -14.99%. DENTSPLY SIRONA's return on equity of 20.84% beat Neogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neogen	-0.91%	2.78%	1.74%
DENTSPLY SIRONA	-14.99%	20.84%	5.32%

Summary

Neogen beats DENTSPLY SIRONA on 9 of the 14 factors compared between the two stocks.

Get Neogen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NEOG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NEOG vs. The Competition

Export

Metric	Neogen	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.80B	$5.52B	$7.26B	$13.14B
Dividend Yield	N/A	1.79%	2.57%	12.30%
P/E Ratio	-433.33	25.34	275.79	25.40
Price / Sales	3.26	72.24	695.01	114.48
Price / Cash	15.22	32.72	77.42	51.66
Price / Book	1.35	5.69	10.46	6.33
Net Income	-$7.90M	$151.55M	$3.49B	$358.33M
7 Day Performance	10.36%	0.66%	0.59%	1.12%
1 Month Performance	7.00%	-3.83%	-2.01%	-2.67%
1 Year Performance	131.73%	6.86%	18.09%	6.01%

Neogen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NEOG Neogen	1.7086 of 5 stars	$13.00 +1.3%	$12.00 -7.7%	+129.3%	$2.80B	$870.40M	N/A	1,257	High Trading Volume
BLCO Bausch + Lomb	3.671 of 5 stars	$18.03 -0.1%	$18.75 +4.0%	+9.4%	$6.44B	$5.10B	N/A	13,000	Analyst Forecast
MMSI Merit Medical Systems	3.4858 of 5 stars	$89.60 flat	$100.00 +11.6%	+1.5%	$5.35B	$1.52B	37.02	7,500	Positive News
NVST Envista	3.4804 of 5 stars	$27.12 -0.6%	$29.71 +9.6%	+11.2%	$4.38B	$2.72B	46.76	12,000	Trending News Analyst Forecast
ICUI ICU Medical	3.8586 of 5 stars	$167.58 flat	$192.80 +15.0%	+14.8%	$4.19B	$2.23B	142.02	13,000

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NEOG) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Neogen (NEOG) Competitors

NEOG vs. BLCO, MMSI, NVST, ICUI, and XRAY

How does Neogen compare to Bausch + Lomb?

Summary

How does Neogen compare to Merit Medical Systems?

Summary

How does Neogen compare to Envista?

Summary

How does Neogen compare to ICU Medical?

Summary

How does Neogen compare to DENTSPLY SIRONA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NEOG vs. The Competition

Neogen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Neogen (NEOG) Competitors

NEOG vs. BLCO, MMSI, NVST, ICUI, and XRAY

How does Neogen compare to Bausch + Lomb?

Which has better valuation and earnings, BLCO or NEOG?

Does the media prefer BLCO or NEOG?

Is BLCO or NEOG more profitable?

Which has more volatility & risk, BLCO or NEOG?

Do analysts prefer BLCO or NEOG?

Do insiders and institutionals have more ownership in BLCO or NEOG?

Summary

How does Neogen compare to Merit Medical Systems?

Which has preferable earnings and valuation, NEOG or MMSI?

Is NEOG or MMSI more profitable?

Do insiders & institutionals have more ownership in NEOG or MMSI?

Does the media refer more to NEOG or MMSI?

Which has more risk & volatility, NEOG or MMSI?

Do analysts recommend NEOG or MMSI?

Summary

How does Neogen compare to Envista?

Which has higher earnings & valuation, NVST or NEOG?

Is NVST or NEOG more profitable?

Which has more volatility & risk, NVST or NEOG?

Do analysts prefer NVST or NEOG?

Do institutionals and insiders believe in NVST or NEOG?

Does the media refer more to NVST or NEOG?

Summary

How does Neogen compare to ICU Medical?

Is NEOG or ICUI more profitable?

Which has better valuation & earnings, NEOG or ICUI?

Do analysts prefer NEOG or ICUI?

Do insiders and institutionals have more ownership in NEOG or ICUI?

Does the media prefer NEOG or ICUI?

Which has more risk and volatility, NEOG or ICUI?

Summary

How does Neogen compare to DENTSPLY SIRONA?

Do analysts prefer NEOG or XRAY?

Do institutionals and insiders hold more shares of NEOG or XRAY?

Does the media favor NEOG or XRAY?

Which has higher earnings & valuation, NEOG or XRAY?

Which has more risk & volatility, NEOG or XRAY?

Is NEOG or XRAY more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NEOG vs. The Competition

Neogen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools